Efficacy of once-daily oxybutynin patch add-on therapy with α1-blocker in male patients with benign prostatic hyperplasia and overactive bladder
Non-Moderated Poster Session
12:30 PM - 1:30 PM
Masaki Watanabe (1)
(1) Asahikawa Medical University Hospital, Asahikawa, Japan
There are many reports in which oral type anticholinergic drugs were additionally administered to male patients with benign prostatic hyperplasia (BPH) who had overactive bladder (OAB) symptoms while taking α1-blockers.1) However, there are no reports on the efficacy of transdermal absorption type anticholinergics add-on therapy with α1-blocker .Therefore, the efficacy of once-daily oxybutynin patch add-on therapy with α1-blocker was examined in male patients with BPH and OAB.
Male patients who had BPH and persistent OAB symptoms after 4 or more weeks of α1-blocker monotherapy were randomly allocated to another 4-week treatment with α1-blocker alone (14 patients) or α1-blocker with once-daily oxybutynin patch (14 patients).
IPSS total score, IPSS storage symptom score, QOL-index, OABSS total score and urgency score of OABSS were significantly improved in patients with once-daily oxybutynin patch, but not in those with α1-blocker alone. Maximum flow rate and postvoid residual volume were not changed significantly in either group.
These data suggest that add-on therapy of once-daily oxybutynin patch with α1-blocker is effective in improving storage symptoms in men with BPH who had persistent OAB symptoms despite taking α1-blocker.